title: Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration.
abstract: BACKGROUND
  Ranibizumab and bevacizumab are used widely for treating patients with choroidal neovascular membrane (CNVM) secondary to age-related macular degeneration (AMD).
  
  
  OBJECTIVE
  To determine and compare the efficacy and safety of intravitreal ranibizumab and bevacizumab in treatment of CNVM due to AMD.
  
  
  METHODS
  Prospective comparative case series carried out in an eye institute and eye department of a hospital in Kolkata, India.
  
  
  METHODS
  One hundred and four eyes with CNVM due to AMD were randomized into two groups. Group A (n=54; 24 occult) received monthly intravitreal ranibizumab injections (0.5 mg in 0.05 ml) and Group B (n=50; 22 occult) received monthly bevacizumab injections (1.25 mg in 0.05 ml) for 3 consecutive months and then as per study criteria. Data analysis done using SPSS software. P-value of <0.05 was considered statistically significant.
  
  
  RESULTS
  The mean best corrected visual acuity (BCVA) in the ranibizumab group increased from 58.19 Early Treatment Diabetic Retinopathy Study (ETDRS) letters at baseline to 64 ETDRS letters at month 3 (P<0.001). In bevacizumab group mean BCVA increased from 56.80 to 61.72 ETDRS letters at month 3 (P<0.001). At the end of 18 months, there was no statistically significant difference between groups A and B with respect to change in BCVA (P=0.563) or central macular thickness (CMT; P=0.281), as measured by optical coherence tomography (Stratus OCT 3000). No significant sight-threatening complications developed.
  
  
  CONCLUSIONS
  Ranibizumab and bevacizumab are equally safe and efficacious in treating CNVM due to AMD.
authors.affiliation: B. B. Eye Foundation, 2/5, Sarat Bose Road, Kolkata - 700 020, India. drpartha_biswas07@yahoo.co.in
authors.forename: Partha
authors.initials: P
authors.lastname: Biswas
authors.forename: Subhrangshu
authors.initials: S
authors.lastname: Sengupta
authors.forename: Ruby
authors.initials: R
authors.lastname: Choudhary
authors.forename: Subhankar
authors.initials: S
authors.lastname: Home
authors.forename: Ajoy
authors.initials: A
authors.lastname: Paul
authors.forename: Sourav
authors.initials: S
authors.lastname: Sinha
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology*; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000150:complications*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D000069579:Ranibizumab; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000069579:Ranibizumab